MetaCap

ANI Pharmaceuticals Inc. (ANIP)

NASDAQ: ANIPHealth CareBiotechnology: Pharmaceutical PreparationsUSD

68.55-0.58 (-0.84%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ANIP stock chart

Technical analysis

Key statistics

All statistics
52-week range
67.14 – 87.76
Day range
68.28 – 70.20
Volume / Avg
227.26K / 420.66K
Beta
—

52-week range

$67.14$87.76

ANIP stock today

ANI Pharmaceuticals (ANIP) closed at $68.55 on Nov 20, down 0.84% (-$0.58), versus the S&P 500's 3.70% decline. At this level, ANIP sits near the bottom of its 52-week range of $67.14 to $87.76: 21.9% below the high, set on May 8, 2026 and 2.1% above the low. ANIP is down 13.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 14.0%.

ANI Pharmaceuticals trades at 13.9x its trailing twelve-month earnings per share of $4.93. Its forward P/E of 6.7x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About ANI Pharmaceuticals

Company profile

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Nikhil Lalwani
Headquarters
Princeton, NJ
Employees
970

Financial highlights

Full financials

In fiscal 2025, ANI Pharmaceuticals generated $883.4 million in revenue, up 43.8% from fiscal 2024, its 14th consecutive year of revenue growth. Net income was $78.3 million, for a net margin of 8.9% versus a median of -10.8% in the prior 5 years. Gross margin was 61.4% (up from 59.3%) and operating margin 12.6%.

ANI Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$883.37M$614.38M$486.82M$316.38M$216.14M
Growth+43.78%+26.20%+53.87%+46.38%+3.67%
Net income$78.34M$-18.52M$18.78M$-47.90M$-42.60M
EPS (diluted)$3.32$-1.04$0.85$-3.05$-3.40

Analyst forecast

Forecast

Consensus (8 analysts)

buy

Avg. price target

$103.38+50.81%

  • Strong buy 3
  • Buy 3
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $85.00High $121.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$1.51 vs $1.80
Surprise
-16.11%

ANIP news

All ANIP news

ANI Pharmaceuticals peers

Health Care sector
ANIP peer companies
CompanyPrice% ChgMarket capCompare
ZBIOZenas BioPharma Inc.23.85-4.75%$1.62Bvs ANIP
PGENPrecigen Inc.4.21+1.20%$1.51Bvs ANIP
AGIOAgios Pharmaceuticals Inc.27.60-4.03%$1.65Bvs ANIP
BRVEBraveheart Bio Inc.20.39+5.81%$1.67Bvs ANIP
RAREUltragenyx Pharmaceutical Inc.16.48-4.30%$1.68Bvs ANIP
DMRADamora Therapeutics Inc.23.22-4.44%$1.44Bvs ANIP
KLRAKailera Therapeutics Inc.11.02-4.84%$1.43Bvs ANIP
KRSAKorsana Biosciences Inc.37.56+5.95%$1.71Bvs ANIP

Indexes, lists and sector

ANI Pharmaceuticals stock FAQ

What is ANI Pharmaceuticals's stock price today?

ANIP last traded at $68.55 as of Nov 20, 4:00 PM EST, down 0.84% on the day. Prices are delayed at least 15 minutes.

Does ANI Pharmaceuticals pay a dividend?

No. ANI Pharmaceuticals does not currently pay a regular cash dividend.

What is ANIP's P/E ratio?

ANIP trades at a trailing P/E ratio of 13.90 and a forward P/E of 6.72.

Who is ANI Pharmaceuticals's CEO?

Mr. Nikhil Lalwani is the chief executive officer of ANI Pharmaceuticals Inc., which has about 970 employees.

Has ANIP ever split its stock?

Yes. The most recent ANIP stock split was a 1-for-6 split on Jul 18, 2013, one of 3 splits on record.

What is the ANIP 52-week high?

The 52-week high for ANIP is $87.76 and the 52-week low is $67.14. The stock is currently 21.9% below its high.

Compare ANIP